Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Annual and Special Virtual-Only Meeting

Stock Information for Zomedica Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zomedica Corp.

Zomedica Expands International Reach with CE Certification for VetGuardian(R) System
Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform
Zomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ET
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
Zomedica Provides NYSE American Listing Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.